vs
Bone Biologics Corp（BBLG）与CollPlant Biotechnologies Ltd（CLGN）财务数据对比。点击上方公司名可切换其他公司
CollPlant Biotechnologies Ltd的季度营收约是Bone Biologics Corp的702.0倍（$179.0K vs $255）。CollPlant Biotechnologies Ltd净利率更高（-1869.8% vs -339596.1%，领先337726.2%）。CollPlant Biotechnologies Ltd同比增速更快（-28.1% vs -54.1%）
Bone Biologics Corp是一家临床阶段生物技术企业，专注研发用于脊柱融合等骨科手术的骨再生修复生物制剂，主要面向美国医疗市场，核心业务覆盖骨科护理及再生医学领域。
CollPlant Biotechnologies是一家再生医疗企业，依托专有的植物源人胶原蛋白技术，开发并商业化伤口护理、软组织修复、医美领域的创新产品，主要面向北美、欧洲及以色列市场，服务皮肤科、骨科和医美领域的医疗从业者。
BBLG vs CLGN — 直观对比
营收规模更大
CLGN
是对方的702.0倍
$255
营收增速更快
CLGN
高出26.0%
-54.1%
净利率更高
CLGN
高出337726.2%
-339596.1%
损益表 — Q1 2024 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $255 | $179.0K |
| 净利润 | $-866.0K | $-3.3M |
| 毛利率 | — | -3.9% |
| 营业利润率 | -354327.8% | -1775.4% |
| 净利率 | -339596.1% | -1869.8% |
| 营收同比 | -54.1% | -28.1% |
| 净利润同比 | 76.7% | 20.5% |
| 每股收益（稀释后） | $-1.31 | $0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BBLGCLGN
| Q2 25 | — | $179.0K | ||
| Q2 24 | — | $249.0K | ||
| Q1 24 | $255 | — | ||
| Q4 23 | $348 | — | ||
| Q3 23 | $536 | — | ||
| Q2 23 | $428 | $10.2M | ||
| Q1 23 | $556 | — | ||
| Q2 22 | — | $66.0K |
净利润BBLGCLGN
| Q2 25 | — | $-3.3M | ||
| Q2 24 | — | $-4.2M | ||
| Q1 24 | $-866.0K | — | ||
| Q4 23 | $-1.5M | — | ||
| Q3 23 | $-1.9M | — | ||
| Q2 23 | $-1.8M | $5.8M | ||
| Q1 23 | $-3.7M | — | ||
| Q2 22 | — | $-4.3M |
毛利率BBLGCLGN
| Q2 25 | — | -3.9% | ||
| Q2 24 | — | -115.3% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 94.0% | ||
| Q1 23 | — | — | ||
| Q2 22 | — | 34.8% |
营业利润率BBLGCLGN
| Q2 25 | — | -1775.4% | ||
| Q2 24 | — | -1769.5% | ||
| Q1 24 | -354327.8% | — | ||
| Q4 23 | -333335.6% | — | ||
| Q3 23 | -388225.7% | — | ||
| Q2 23 | -710249.5% | 55.7% | ||
| Q1 23 | -566103.8% | — | ||
| Q2 22 | — | -6340.9% |
净利率BBLGCLGN
| Q2 25 | — | -1869.8% | ||
| Q2 24 | — | -1690.8% | ||
| Q1 24 | -339596.1% | — | ||
| Q4 23 | -445369.3% | — | ||
| Q3 23 | -358154.7% | — | ||
| Q2 23 | -413373.4% | 56.6% | ||
| Q1 23 | -667248.0% | — | ||
| Q2 22 | — | -6492.4% |
每股收益（稀释后）BBLGCLGN
| Q2 25 | — | $0.28 | ||
| Q2 24 | — | $0.37 | ||
| Q1 24 | $-1.31 | — | ||
| Q4 23 | $31.30 | — | ||
| Q3 23 | $-4.90 | — | ||
| Q2 23 | $-5.21 | $0.49 | ||
| Q1 23 | $-55.20 | — | ||
| Q2 22 | — | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $11.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.7M | $12.5M |
| 总资产 | $3.8M | $17.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BBLGCLGN
| Q2 25 | — | $11.4M | ||
| Q2 24 | — | $18.9M | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $22.3M | ||
| Q1 23 | $6.2M | — | ||
| Q2 22 | — | $36.3M |
股东权益BBLGCLGN
| Q2 25 | — | $12.5M | ||
| Q2 24 | — | $20.7M | ||
| Q1 24 | $3.7M | — | ||
| Q4 23 | $2.9M | — | ||
| Q3 23 | $3.8M | — | ||
| Q2 23 | $5.7M | $36.0M | ||
| Q1 23 | $2.8M | — | ||
| Q2 22 | — | $39.5M |
总资产BBLGCLGN
| Q2 25 | — | $17.4M | ||
| Q2 24 | — | $26.6M | ||
| Q1 24 | $3.8M | — | ||
| Q4 23 | $3.7M | — | ||
| Q3 23 | $5.0M | — | ||
| Q2 23 | $7.6M | $41.6M | ||
| Q1 23 | $6.8M | — | ||
| Q2 22 | — | $44.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.3M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BBLGCLGN
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-1.3M | — | ||
| Q4 23 | $-2.0M | — | ||
| Q3 23 | $-2.6M | — | ||
| Q2 23 | $-3.6M | — | ||
| Q1 23 | $-1.3M | — | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
